Terms: = Prostate cancer AND FOXA1, TCF3A, 3169, ENSG00000129514, P55317, HNF3A, MGC33105 AND Treatment
53 results:
1. Clinically-observed foxa1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract] [Full Text] [Related]
2. Chromatin accessibility and pioneer factor foxa1 restrict glucocorticoid receptor action in prostate cancer.
Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
[TBL] [Abstract] [Full Text] [Related]
3. Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in prostate cancer.
Grillo G; Keshavarzian T; Linder S; Arlidge C; Mout L; Nand A; Teng M; Qamra A; Zhou S; Kron KJ; Murison A; Hawley JR; Fraser M; van der Kwast TH; Raj GV; He HH; Zwart W; Lupien M
Cancer Discov; 2023 Nov; 13(11):2470-2487. PubMed ID: 37694973
[TBL] [Abstract] [Full Text] [Related]
4. Lysosome-dependent foxa1 ubiquitination contributes to luminal lineage of advanced prostate cancer.
Celada SI; Li G; Celada LJ; Lu W; Kanagasabai T; Feng W; Cao Z; Salsabeel N; Mao N; Brown LK; Mark ZA; Izban MG; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Wang X; Chen Z
Mol Oncol; 2023 Oct; 17(10):2126-2146. PubMed ID: 37491794
[TBL] [Abstract] [Full Text] [Related]
5. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases.
Sattari M; Kohvakka A; Moradi E; Rauhala H; Urhonen H; Isaacs WB; Nykter M; Murtola TJ; Tammela TLJ; Latonen L; Bova GS; Kesseli J; Visakorpi T
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37140987
[TBL] [Abstract] [Full Text] [Related]
6. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant prostate cancer.
Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
[TBL] [Abstract] [Full Text] [Related]
7. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive prostate cancer toward Androgen Independence.
Linder S; Hoogstraat M; Stelloo S; Eickhoff N; Schuurman K; de Barros H; Alkemade M; Bekers EM; Severson TM; Sanders J; Huang CF; Morova T; Altintas UB; Hoekman L; Kim Y; Baca SC; Sjöström M; Zaalberg A; Hintzen DC; de Jong J; Kluin RJC; de Rink I; Giambartolomei C; Seo JH; Pasaniuc B; Altelaar M; Medema RH; Feng FY; Zoubeidi A; Freedman ML; Wessels LFA; Butler LM; Lack NA; van der Poel H; Bergman AM; Zwart W
Cancer Discov; 2022 Sep; 12(9):2074-2097. PubMed ID: 35754340
[TBL] [Abstract] [Full Text] [Related]
8. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
Liao Y; Chen CH; Xiao T; de la Peña Avalos B; Dray EV; Cai C; Gao S; Shah N; Zhang Z; Feit A; Xue P; Liu Z; Yang M; Lee JH; Xu H; Li W; Mei S; Pierre RS; Shu S; Fei T; Duarte M; Zhao J; Bradner JE; Polyak K; Kantoff PW; Long H; Balk SP; Liu XS; Brown M; Xu K
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35031563
[TBL] [Abstract] [Full Text] [Related]
10. Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.
Long MD; Jacobi JJ; Singh PK; Llimos G; Wani SA; Rowsam AM; Rosario SR; Hoogstraat M; Linder S; Kirk J; Affronti HC; Bergman A; Zwart W; Campbell MJ; Smiraglia DJ
Cell Rep; 2021 Dec; 37(11):110109. PubMed ID: 34910907
[TBL] [Abstract] [Full Text] [Related]
11. Prognosis Associated With Luminal and Basal Subtypes of Metastatic prostate cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract] [Full Text] [Related]
12. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized prostate cancer Via Targeted, Multiregion Sequencing.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
[TBL] [Abstract] [Full Text] [Related]
13. A deep imputation and inference framework for estimating personalized and race-specific causal effects of genomic alterations on PSA.
Chen Z; Cao B; Edwards A; Deng H; Zhang K
J Bioinform Comput Biol; 2021 Aug; 19(4):2150016. PubMed ID: 34225568
[TBL] [Abstract] [Full Text] [Related]
14. Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant cancer Cells.
Uddin MH; Li Y; Khan HY; Muqbil I; Aboukameel A; Sexton RE; Reddy S; Landesman Y; Kashyap T; Azmi AS; Heath EI
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206543
[TBL] [Abstract] [Full Text] [Related]
15. Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer.
Takayama KI; Kosaka T; Suzuki T; Hongo H; Oya M; Fujimura T; Suzuki Y; Inoue S
Nat Commun; 2021 Jun; 12(1):3766. PubMed ID: 34145268
[TBL] [Abstract] [Full Text] [Related]
16. Reprogramming of the foxa1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
[TBL] [Abstract] [Full Text] [Related]
17. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
[TBL] [Abstract] [Full Text] [Related]
18. Epidemiology and genomics of prostate cancer in Asian men.
Zhu Y; Mo M; Wei Y; Wu J; Pan J; Freedland SJ; Zheng Y; Ye D
Nat Rev Urol; 2021 May; 18(5):282-301. PubMed ID: 33692499
[TBL] [Abstract] [Full Text] [Related]
19. Patient-derived xenografts and organoids model therapy response in prostate cancer.
Karkampouna S; La Manna F; Benjak A; Kiener M; De Menna M; Zoni E; Grosjean J; Klima I; Garofoli A; Bolis M; Vallerga A; Theurillat JP; De Filippo MR; Genitsch V; Keller D; Booij TH; Stirnimann CU; Eng K; Sboner A; Ng CKY; Piscuoglio S; Gray PC; Spahn M; Rubin MA; Thalmann GN; Kruithof-de Julio M
Nat Commun; 2021 Feb; 12(1):1117. PubMed ID: 33602919
[TBL] [Abstract] [Full Text] [Related]
20. Pioneer of prostate cancer: past, present and the future of foxa1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract] [Full Text] [Related]
[Next]
